PrognomiQ

San Mateo, United States Founded: 2020 • Age: 6 yrs
Developer of tests for the detection and treatment of cancer and other diseases

About PrognomiQ

PrognomiQ is a Healthcare company based in San Mateo (United States) founded in 2020 by Philip Ma and Omid Farokhzad. Developer of tests for the detection and treatment of cancer and other diseases. PrognomiQ has raised $102.24 million across 4 funding rounds from investors including Fidelity Investments, T. Rowe Price and Bruker. The company has 24 employees. Its chief executive, as recorded, is Philip Ma. PrognomiQ offers products and services including Multi-Omics Tests and Proteomic Data Services. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is PROGNOMIQ, INC. Its competitors include ACRO Biosystems, List Biological Laboratories and Ansh Labs; 1 of its 3 listed competitors has raised funding.

Company details

Founded in 2020 and headquartered in San Mateo, United States, PrognomiQ operates in the health technology sector. Diagnostic tests are developed by the company to identify cancer and other diseases at early stages. Proteomic data is integrated with genomic, metabolomic, and additional health information to support detection and treatment strategies. Operations focus on advancing personalized medicine through multi-omics approaches.

  • Headquarters San Mateo, United States
  • Employees 24
  • Founders Philip Ma, Omid Farokhzad
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website prognomiq.com
  • Social LinkedIn X
  • Legal Name Prognomiq, Inc.
Key Metrics
  • Total Equity Funding
    $102.24M (USD)

    in 4 rounds

  • Latest Funding Round
    $11.87M (USD), Series D

    Jan 2026

  • Investors
  • Employee Count
    24

Products & Services of PrognomiQ

PrognomiQ offers a comprehensive portfolio of products and services, including Multi-Omics Tests and Proteomic Data Services.

Multi-Omics Tests
Diagnostic Platforms

Enables early detection of diseases using integrated proteomics data.

Proteomic Data Services
Analytical Tools

Provides insights into disease mechanisms via large-scale protein analysis.

Funding Insights of PrognomiQ

PrognomiQ has successfully raised a total of $102.24M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $11.87 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $102.24M
  • Total Rounds 4
  • Last Round Series D β€” $11.87M
  • First Round $46M

    (Mar 2022)

  • Investors Count 10

All 4 funding rounds of PrognomiQ with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2026$11.87MSeries D––
–
Aug 2025$10.05MSeries D––
–
Aug 2024$34.32MSeries D–Seer
Mar 2022$46MSeries C–Bruker
Valuation history

10 investors in total: 10 institutional.

Investors in PrognomiQ

PrognomiQ has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Bruker.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital is provided to biomedical technology startups.
cataliocapital.comNew York, United States
Venture capital investments in healthcare are focused on by aMoon.
amoon.fund
Long-term private equity investments in transformational opportunities are pursued.
invus.comNew York, United States
Early-stage tech and life-sciences firms are funded across the US.
maverickventures.comSan Francisco, United States
Venture capital fund and fund of funds focused on early-stage startups
wing.vcPalo Alto, United States
Proteomics platform developed for early cancer and neurological disease detection.
2017seer.bioSan Francisco, United States
Diversified research instrument systems are manufactured and supplied.
1960bruker.comUnited States
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
1946fidelity.comBoston, United States
Diversified asset management services are provided to investors globally.
1937troweprice.comBaltimore, United States
emersoncollective.com
Premium access

Investor details for PrognomiQ

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of PrognomiQ

39 people are tracked at PrognomiQ (11 in leadership, 14 in board & advisors, 14 in team); the tracked headcount is 24.

NameRoleGroup
Philip Ma
Co-Founder & CEOLeadership
Omid Farokhzad
Co-FounderLeadership
Bruce Wilcox
CTOLeadership
Bob Zawada
Senior Director Product DevelopmentLeadership
David Siewers
CFOLeadership
Joel Kaufman
Chief Financial OfficerLeadership
Madhuvanthi Ramaiah
VP Of Product Management & PMOLeadership
Yi (Jimmy) Zeng
Associate Director of Mass SpectrometryLeadership
Nithya S Mudaliar
Head Of Clinical OperationsLeadership
Sandra Golez Meily
Executive Assistant To Chief Executive OfficerLeadership
Brian Koh
Chief Medical OfficerLeadership
Tomer Berkovitz
DirectorBoard & advisors
Philip Kantoff
Scientific & Clinical AdvisorBoard & advisors
Charles Cantor
Scientific AdvisorBoard & advisors
Robert Langer
Scientific AdvisorBoard & advisors
Mark Lee
Scientific & Clinical AdvisorBoard & advisors
Alfred Sandrock
Scientific & Clinical AdvisorBoard & advisors
Steven Carr
Scientific AdvisorBoard & advisors
Catherine Ball
Scientific AdvisorBoard & advisors
Ernest Fraenkel
Scientific AdvisorBoard & advisors

19 more people are available in the full profile.

Premium access

Complete people profiles for PrognomiQ

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of PrognomiQ

3 dated milestones of PrognomiQ across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded PrognomiQ is founded.
  2. Funding First funding round of $46.0M.
  3. Funding Latest funding round, Series D, of $11.9M.

Competitors of PrognomiQ

PrognomiQ has 3 listed competitors in our database, 1 of them funded. They include ACRO Biosystems, List Biological Laboratories and Ansh Labs.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
acrobiosystems.com2016Newark, United States22
Recombinant proteins are manufactured to support cancer immunotherapy efforts.
listlabs.com1978Campbell, United States$48.4M
Specializes in the production of research reagents
anshlabs.com2010Webster, United States33
Immunoassay reagents and kits are developed for life science research.
Premium access

Detailed competitors of PrognomiQ

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of PrognomiQ

The website of PrognomiQ (prognomiq.com) receives about 2.6K visits a month.

  • Monthly visits
    2.6K

    ▲ 151.6% vs previous month

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as PrognomiQ (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Prognomiq

Premium access

Complete news archive for PrognomiQ

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about PrognomiQ

PrognomiQ was founded in 2020 and raised its 1st funding round 2 years after it was founded.

PrognomiQ is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.

Philip Ma is the CEO of PrognomiQ, as recorded in our data. They have also founded this company.

PrognomiQ is a funded company, having raised a total of $102.24M across 4 funding rounds to date. The company's 1st funding round was a Series C of $46M, raised on Mar 2022.

PrognomiQ has 24 employees.

Founded in 2020 and headquartered in San Mateo, United States, PrognomiQ operates in the health technology sector. Diagnostic tests are developed by the company to identify cancer and other diseases at early stages. Proteomic data is integrated with genomic, metabolomic, and additional health information to support detection and treatment strategies. Operations focus on advancing personalized medicine through multi-omics approaches.

PrognomiQ's top competitors include ACRO Biosystems, Ansh Labs and List Biological Laboratories.

PrognomiQ offers Multi-Omics Tests and Proteomic Data Services.

PrognomiQ has 10 investors. Key investors include Fidelity Investments, T. Rowe Price, Bruker, Seer, and Catalio Capital Management.

PrognomiQ operates through Prognomiq, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available